Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is a clinical-stage biotechnology company with a promising pipeline of product candidates focused on three therapeutic areas. The company's proprietary Native Complex Platform is expected to unlock the full potential of GPCR therapies, giving it a strong competitive advantage. Based on positive Phase 1 trial results for SEP-479, a once-daily oral PTH1R agonist, and promising preclinical data for SEP-631, a MRGPRX2 receptor agonist, analysts are bullish on the company's potential success in the market. Septerna's strong financial position, with $516.5M in cash and marketable securities, and partnerships with companies like Novo Nordisk further support this positive outlook.

Bears say

Septerna is a clinical-stage biotechnology company with a narrow focus on GPCR oral small molecule drug discovery. Despite positive Phase 1 results for its lead candidate SEP-631, there is substantial risk for the company's planned Phase 2 studies given the disappointing data from Evommune's similar candidate. This risk, combined with the company's reliance on one single platform and narrow pipeline, leads to a negative outlook for the stock.

Septerna Inc (SEPN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.